PRTC vs. COGT, ARCT, SIGA, AUPH, IRON, YMAB, SVRA, WVE, DNTH, and MLYS
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Cogent Biosciences (COGT), Arcturus Therapeutics (ARCT), SIGA Technologies (SIGA), Aurinia Pharmaceuticals (AUPH), Disc Medicine (IRON), Y-mAbs Therapeutics (YMAB), Savara (SVRA), Wave Life Sciences (WVE), Dianthus Therapeutics (DNTH), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical preparations" industry.
Cogent Biosciences (NASDAQ:COGT) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, community ranking, institutional ownership and media sentiment.
0.0% of PureTech Health shares are held by institutional investors. 5.9% of Cogent Biosciences shares are held by company insiders. Comparatively, 5.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Cogent Biosciences had 26 more articles in the media than PureTech Health. MarketBeat recorded 27 mentions for Cogent Biosciences and 1 mentions for PureTech Health. Cogent Biosciences' average media sentiment score of 1.87 beat PureTech Health's score of 0.24 indicating that PureTech Health is being referred to more favorably in the news media.
Cogent Biosciences' return on equity of 0.00% beat PureTech Health's return on equity.
PureTech Health has higher revenue and earnings than Cogent Biosciences.
Cogent Biosciences has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.
Cogent Biosciences received 267 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 70.80% of users gave Cogent Biosciences an outperform vote while only 38.89% of users gave PureTech Health an outperform vote.
Cogent Biosciences presently has a consensus target price of $14.67, suggesting a potential upside of 95.56%. Given PureTech Health's higher probable upside, equities research analysts clearly believe Cogent Biosciences is more favorable than PureTech Health.
Summary
Cogent Biosciences beats PureTech Health on 7 of the 13 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PureTech Health Competitors List
Related Companies and Tools
